Scholarlink

Objective <p>Myofascial Pain Disorder Syndrome (MPDS) is the most common temporomandibular disorder, affecting nearly 90% of cases with masticatory muscle involvement. This study aimed to compare the therapeutic effects of photobiomodulation (PBM) with Meloxicam on pain reduction and improvement of jaw function.</p> Methods <p>Twenty-eight patients with chronic masticatory muscle pain were randomly assigned into two groups: PBM therapy and Meloxicam treatment. Maximum mouth opening and muscle pain (at rest and during function) were measured before treatment. Pain intensity was assessed using the Visual Analog Scale (VAS). Patients in the drug group received 7.5&#xa0;mg Meloxicam twice daily for three weeks, while patients in the PBM group underwent twelve sessions of 810&#xa0;nm diode Photobiomodulation. At the end of treatment, and again at two-month follow-up, pain and maximum mouth opening were recorded and compared.</p> Results <p>Both groups showed improvement, but pain relief and mouth-opening function were more significant in the PBM group. During follow-up, PBM maintained its therapeutic effects, while relapse occurred in the Meloxicam group.</p> Conclusion <p>Compared with Meloxicam, 810&#xa0;nm PBM therapy provided greater and longer-lasting improvements in pain reduction and jaw function which can suggest PBM as an effective and Non-invasive alternative for managing MPDS.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Photobiomodulation versus Meloxicam in myofascial pain disorder syndrome: a double-blind clinical trial study

  • 期刊论文

  • 发表日期：

    2026年5月22日

查看全文
  • Hamed Haji Mokhtari,
  • Sepehr Miramirkhany,
  • Robab Noormohammadi

摘要

Objective

Myofascial Pain Disorder Syndrome (MPDS) is the most common temporomandibular disorder, affecting nearly 90% of cases with masticatory muscle involvement. This study aimed to compare the therapeutic effects of photobiomodulation (PBM) with Meloxicam on pain reduction and improvement of jaw function.

Methods

Twenty-eight patients with chronic masticatory muscle pain were randomly assigned into two groups: PBM therapy and Meloxicam treatment. Maximum mouth opening and muscle pain (at rest and during function) were measured before treatment. Pain intensity was assessed using the Visual Analog Scale (VAS). Patients in the drug group received 7.5 mg Meloxicam twice daily for three weeks, while patients in the PBM group underwent twelve sessions of 810 nm diode Photobiomodulation. At the end of treatment, and again at two-month follow-up, pain and maximum mouth opening were recorded and compared.

Results

Both groups showed improvement, but pain relief and mouth-opening function were more significant in the PBM group. During follow-up, PBM maintained its therapeutic effects, while relapse occurred in the Meloxicam group.

Conclusion

Compared with Meloxicam, 810 nm PBM therapy provided greater and longer-lasting improvements in pain reduction and jaw function which can suggest PBM as an effective and Non-invasive alternative for managing MPDS.